Skip to content

Wet-suction Versus Slow-pull for EUS-FNB of Solid Lesions

Wet-suction Versus Slow-pull Technique for Endoscopic Ultrasound-guided Fine-needle Biopsy of Solid Lesions: a Multicentric Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04834193
Acronym
WEST-FNB
Enrollment
200
Registered
2021-04-08
Start date
2021-03-29
Completion date
2022-04-30
Last updated
2023-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic Ultrasound, Fine-needle Aspiration

Brief summary

A randomized cross-over study investigating the impact of two different suction techniques on histological yield and sample quality of specimens collected by endoscopic ultrasound biopsy from solid lesions using histology needles.

Interventions

PROCEDUREEndoscopic ultrasound-guided fine-needle biopsy

Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)

Sponsors

Azienda Ospedaliera Universitaria Integrata Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Solid pancreatic lesions 3 1cm * Peri-GI tract lymph nodes 3 1cm * Peri-GI tract masses * Lesions of the GI wall * Signed informed consent

Exclusion criteria

* Pancreatic cystic lesions (more than 50% of the volume) * Diameter of lesion ≤ 1 cm * Lesion not seen at EUS * Pregnancy * Coagulopathy (platelet count \<50.000/mm3 and/or international normalized ratio \>1.5); * Severe cardiorespiratory dysfunction precluding endoscopy; * Failure to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Histologic yield6 monthsThe rate of samples containing a tissue core (yes/no) for histological evaluation, defined as an intact piece of tissue of at least 550 μ

Secondary

MeasureTime frameDescription
Tissue integrity6 monthsTissue integrity will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system: 0: No cells/tissue 1. Cytological specimen (disaggregated cells representative of the target lesion not allowing for tissue architectural assessment) 2. Histologic microfragments (sample adequate for histological evaluation, namely an architecturally intact piece of tissue but without a core) 3. Histologic core (defined as an architecturally intact piece of tissue measuring at least 550 μ)
Blood contamination6 monthsBlood contamination will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system: 0: Only blood 1. High blood contamination (\>50% of the surface) 2. Moderate blood contamination (25-50% of the surface) 3. Low blood contamination (\<25% of the surface)
Tumor fraction6 monthsThe rate of samples containing an adequate tumor fraction ≥20 percent (i.e., ≥ 20 percent tumor cells in a background of benign nucleated cells).
Diagnostic accuracy6 monthsDiagnostic accuracy (defined as the ratio between the sum of true positive and true negative values divided by the number of lesions) will be calculated for each study arm

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026